Initial Treatment for Pericarditis

First-Line Treatment

• The European Society of Cardiology recommends aspirin (750-1000 mg every 8 hours) or ibuprofen (600 mg every 8 hours) as first-line therapy for 1-2 weeks with gastroprotection 1, 2
• The choice between NSAIDs should be based on patient history, concomitant diseases, and contraindications 3
• Treatment duration should be guided by symptoms and C-reactive protein (CRP) normalization 1
• Tapering should be considered by decreasing doses gradually (e.g., aspirin by 250-500 mg every 1-2 weeks) 1, 2
• Colchicine should be added to NSAIDs/aspirin as part of first-line therapy 1, 2
• Weight-adjusted dosing is recommended: 0.5 mg once daily if <70 kg or 0.5 mg twice daily if ≥70 kg 1
• Treatment duration for colchicine should be 3 months 1, 2

Treatment Algorithm

• For non-high-risk cases, outpatient management with NSAIDs and colchicine is recommended 1, 4
• Monitor response using CRP to guide treatment length and assess response 1
• Treatment adjustment: If no response to NSAIDs and colchicine, consider second-line therapy 1

Second-Line Treatment

• Low-dose corticosteroids should be considered only in cases of contraindication to NSAIDs/colchicine, failure of first-line therapy, or when infectious causes have been excluded 1, 4
• If corticosteroids are necessary, use low to moderate doses (prednisone 0.2-0.5 mg/kg/day) rather than high doses 1
• Corticosteroids are NOT recommended as first-line therapy due to risk of promoting chronicity, recurrences, and side effects 1, 5

Special Considerations

• Exercise restriction should be considered until symptoms resolve and CRP, ECG, and echocardiogram normalize 1
• For athletes, exercise restriction should last at least 3 months 1
• Tapering of medications should only be attempted when symptoms are absent and CRP is normal 5

Pitfalls and Caveats

• Inadequate treatment of the first episode is a common cause of recurrence 6
• Corticosteroids provide rapid symptom control but may increase risk of chronicity and recurrence 5
• Recurrence rates after initial episode range from 15-30% without colchicine, increasing to 50% after first recurrence 6
• Risk of constrictive pericarditis varies by etiology: low (<1%) for idiopathic/viral, intermediate (2-5%) for autoimmune/neoplastic, and high (20-30%) for bacterial causes 6
• Cardiac tamponade rarely occurs in idiopathic pericarditis but is more common with specific etiologies like malignancy or purulent pericarditis 6

Colchicine Therapy for Pericardial Effusion

Indications and Contraindications

• The European Society of Cardiology recommends colchicine for pericardial effusion associated with acute pericarditis, but not for isolated pericardial effusion without evidence of systemic inflammation 7
• Colchicine is not indicated for postoperative effusions in the absence of systemic inflammation, as stated by the European Society of Cardiology 8

Diagnostic Criteria

• The European Society of Cardiology guidelines require at least 2 of 5 findings for pericarditis diagnosis, including fever, pericarditic or pleuritic chest pain, pericardial or pleural rubs, evidence of pericardial effusion, and elevated inflammatory markers (CRP) 8

Treatment Approach

• The European Society of Cardiology suggests assessing for inflammation by checking CRP and clinical criteria for pericarditis before initiating colchicine therapy 8
• If inflammation is present, the European Society of Cardiology recommends initiating combination therapy with aspirin or ibuprofen and colchicine (weight-adjusted dosing) 7

Special Considerations

• The European Society of Cardiology advises against using colchicine for asymptomatic post-surgical effusions without inflammation, as it increases side effects without benefit 8
• The European Society of Cardiology notes that inadequate treatment duration (less than 3 months of colchicine) increases recurrence risk 7
• The European Society of Cardiology recommends colchicine for post-cardiac surgery patients only if systemic inflammation is documented 8

Treatment for Moderate Pericardial Effusion with Normal CRP

Critical Distinction: Effusion WITH vs. WITHOUT Inflammation

• The European Heart Society recommends that NSAIDs plus colchicine are first-line therapy for pericardial effusion with pericarditis (elevated CRP) 9, 10
• Aspirin 750-1000 mg every 8 hours OR ibuprofen 600 mg every 8 hours for 1-2 weeks is recommended for pericardial effusion with pericarditis (elevated CRP) 10
• Colchicine 0.5 mg once daily (<70 kg) or twice daily (≥70 kg) for 3 months is recommended for pericardial effusion with pericarditis (elevated CRP) 10
• Treatment duration guided by symptom resolution and CRP normalization is recommended for pericardial effusion with pericarditis (elevated CRP) 10, 11

Isolated Pericardial Effusion WITHOUT Inflammation (Normal CRP)

• Anti-inflammatory drugs are NOT effective for isolated pericardial effusion without inflammation (normal CRP), according to the European Heart Society 9
• Target therapy at the underlying etiology for isolated pericardial effusion without inflammation (normal CRP) 9, 12
• If symptomatic or not responsive to medical therapy, consider pericardiocentesis for isolated pericardial effusion without inflammation (normal CRP) 9, 12
• For large chronic effusions (>3 months), there is a 30-35% risk of progression to tamponade, warranting closer monitoring, as stated by the European Heart Society 9
• The European Heart Society recommends investigating underlying etiology—approximately 60% of effusions are associated with a known disease 9
• Monitor with echocardiography every 6 months for moderate effusions, according to the European Heart Society 9
• Consider pericardiocentesis if patient becomes symptomatic, effusion progresses to large size with tamponade risk, or suspicion of bacterial or neoplastic etiology requiring diagnosis, as recommended by the European Heart Society 9, 12

Pericarditis Management

Special Considerations

• The European Society of Cardiology recommends intensifying dialysis for uraemic pericarditis, and considering pericardial aspiration/drainage if non-responsive 13, 14
• Colchicine is contraindicated in severe renal impairment, as stated by the European Heart Journal 13, 14
• Aggressive management is required for purulent pericarditis, including immediate empiric intravenous antimicrobial therapy and urgent drainage, with a reported 85% survival rate with good long-term outcome 13, 14
• Adjunctive steroids may be considered in HIV-negative tuberculous pericarditis cases, but avoided in HIV-associated TB pericarditis, as per the European Heart Journal 13

Colchicine Use in Acute Kidney Injury with Pericarditis

Diagnostic Confirmation and Treatment

• The European Society of Cardiology recommends establishing a definitive diagnosis of pericarditis using at least 2 of the 4 clinical criteria before considering colchicine therapy in patients with acute kidney injury (AKI) 15
• The European Society of Cardiology suggests that colchicine is contraindicated in severe renal impairment and requires substantial dose reduction in moderate-to-severe AKI, with a recommended starting dose of 0.3 mg once daily for CrCl <30 mL/min 15
• The European Society of Cardiology recommends aspirin 750-1000 mg every 8 hours or ibuprofen 600 mg every 8 hours for 1-2 weeks with gastroprotection as first-line therapy for pericarditis, along with colchicine at renally-adjusted doses for 3 months 15
• The European Society of Cardiology suggests considering low-dose corticosteroids (prednisone 0.2-0.5 mg/kg/day) as second-line therapy if NSAIDs/colchicine are contraindicated by renal dysfunction, after excluding infectious causes 15, 16

Dosing Adjustments and Safety Concerns

• For patients with moderate renal impairment (CrCl 30-50 mL/min), the standard colchicine dose can be used but requires close monitoring for toxicity 15
• For patients on dialysis, the maximum recommended dose of colchicine is 0.3 mg twice weekly 15

Evidence‑Based Treatment Recommendations for Acute Idiopathic or Viral Pericarditis

First‑Line Anti‑Inflammatory Therapy

• Ibuprofen 600 mg every 8 hours (total 1.2–2.4 g/day) is recommended as the primary NSA ​NSAID for acute idiopathic or viral pericarditis. – European Society of Cardiology guideline (Class I, Level B) 17
• Indomethacin 25–50 mg every 8 hours (start at the lower end to minimise headache/dizziness) is an alternative NSAID option. – European Society of Cardiology guideline (Class I, Level B) 17

Combination with Colchicine

• Adding weight‑adjusted colchicine to NSAID therapy reduces recurrence at 18 months from 32 % to 11 % (NNT = 5). – European Society of Cardiology guideline (Class I, Level A) 17

Tapering of NSAID Therapy

• Typical tapering duration ranges from several weeks to a few months, guided by symptom resolution and inflammatory marker normalisation. – European Society of Cardiology guideline 17

Management When NSAIDs Are Contra‑Indicated

• Low‑dose prednisone 0.2–0.5 mg/kg/day combined with colchicine is advised after infectious causes have been excluded. – European Society of Cardiology guideline (Class IIa, Level B) 17
• Absolute NSAID contraindications include true NSAID allergy, recent peptic ulcer or gastrointestinal bleeding, and high‑risk anticoagulant therapy. – European Society of Cardiology guideline 17

Risks Associated with Corticosteroid Use

• Corticosteroids are not first‑line because they markedly increase recurrence risk (odds ratio 4.3, 95 % CI 1.2–15.3). – European Society of Cardiology guideline (Class III, Level B) 17
• Recurrence rate with prednisone + colchicine is ≈40 % versus ≈18 % with NSAID + colchicine. – European Society of Cardiology guideline 17

Importance of Adequate Treatment Duration

• Colchicine must be continued for the full 3 months; shorter courses raise recurrence to 15–30 % after the first episode and up to 50 % after a first recurrence. – European Society of Cardiology guideline 17

Tapering Precautions

• Tapering should only commence after complete symptom resolution and normal CRP; premature tapering leads to rebound inflammation and higher recurrence. – European Society of Cardiology guideline (Class I, Level B) 17

Special Populations

• Pregnancy: Corticosteroids are preferred over NSAIDs, together with weight‑adjusted colchicine. – European Society of Cardiology guideline 17
• Autoimmune disease or post‑pericardiotomy syndrome: First‑line remains NSAID + colchicine; corticosteroids may be added as part of triple therapy when needed. – European Society of Cardiology guideline 17

Management of Pericardial Effusion Associated with Pericarditis

Aspirin Therapy Regimen

• The European Society of Cardiology (ESC) recommends an initial high‑dose aspirin regimen of 750–1000 mg every 8 hours for 1–2 weeks, combined with gastro‑protection, in patients with pericardial effusion and active pericarditis (elevated CRP)【18】.
• Tapering of aspirin should commence only after complete resolution of symptoms and normalization of CRP, to avoid rebound inflammation and recurrence【18】.

Colchicine Adjunctive Therapy

• ESC guidance advises weight‑adjusted colchicine dosing: 0.5 mg once daily for patients < 70 kg, or 0.5 mg twice daily for patients ≥ 70 kg, to be given alongside aspirin in pericarditis‑related effusions【18】.
• For a first episode, colchicine should be continued for a minimum of 3 months; for recurrent pericarditis, the duration should be extended to at least 6 months【18】.

Monitoring and Treatment Duration

• Serial C‑reactive protein (CRP) measurements are required to guide the length of anti‑inflammatory therapy and to confirm therapeutic response【19】【18】.
• Inadequate treatment duration is identified as a common cause of effusion recurrence, emphasizing the need for full symptom resolution and CRP normalization before tapering【19】【18】.

Exercise Restrictions

• Non‑athlete patients should refrain from exercise until symptoms have resolved and CRP, electrocardiogram, and echocardiogram have returned to normal【19】【18】.
• Athletes require a minimum of 3 months of exercise restriction even after symptom resolution, to reduce the risk of recurrence【19】【18】.

Management of Isolated Pericardial Effusion (No Inflammation)

• ESC statements indicate that aspirin and other NSAIDs are ineffective for isolated pericardial effusions with normal CRP; therapy should instead target the underlying cause【20】.
• Pericardiocentesis is recommended when the effusion is symptomatic, unresponsive to etiology‑directed treatment, or when bacterial or neoplastic aetiology is suspected【20】.

Indications for Drainage of Chronic Effusions

• Large chronic effusions persisting > 3 months carry a 30–35 % risk of progression to cardiac tamponade; preventive drainage should be considered【20】.
• Moderate‑size effusions should be monitored with echocardiography at 6‑month intervals to detect progression【20】.

Alternative Therapies (When First‑Line Fails)

• If there is no clinical response to aspirin/NSAIDs plus colchicine, low‑dose corticosteroids (prednisone 0.2–0.5 mg/kg/day) may be introduced after excluding infectious aetiologies【19】【18】.

Use of Colchicine in Pericardial Effusion

Indications

Dosing (when indicated)

Treatment Duration & Recurrence Risk

Monitoring & Follow‑up